Halozyme Therapeutics (HALO) Falls Short of Q4 Views
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $38.64 +2.20%
Revenue Growth %: +27.7%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +27.7%
Financial Fact:
Selling, general and administrative: 11.6M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (Nasdaq: HALO) reported Q4 loss of $0.17, $0.05 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $5.33 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- AmEx surpasses profit estimate; focus turns to small-business strategy
- PPG Industries (PPG) Reports In-Line Q1 EPS, offers outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
